Package Insert: Information for the Patient
Paliperidone Teva 3 mg Extended-Release Tablets EFG
Paliperidone Teva 6 mg Extended-Release Tablets EFG
Paliperidone Teva 9 mg Extended-Release Tablets EFG
Read this package insert carefully before you start taking this medicine because it contains important information for you.
Contents of the package and additional information
Paliperidone Teva contains the active ingredient paliperidone which belongs to the class ofmedicamentosantipsicóticos.
Paliperidone is used to treat schizophrenia in adults and adolescents aged 15 years and older.
Schizophrenia is a disorder that causes symptoms that include hearing, seeing or feeling things thatdonotexist, holding false beliefs, having an abnormal distrust, withdrawing into oneself,speaking incoherently and flattening of behavior and emotion. People with this disorder may also feeldepressed,anxious,guiltyoranxious.
Paliperidone is also used to treat schizoaffective disorder in adults.
Schizoaffective disorder is a mental condition in which the person experiences several of the symptoms of schizophrenia (listed in the previous paragraph) in addition to symptoms of mood disorder (feeling of euphoria, sadness, agitation, being distracted, insomnia, excessive or reduced speech, loss of interest in daily activities, excessive or reduced sleep, excessive or reduced food intake, and recurring thoughts ofsuicidio).
Paliperidone may help alleviate the symptoms of your illness and prevent it fromrelapseting.
Do not takepaliperidone
-if you are allergic to paliperidone, risperidone, or any of the other ingredients in thismedicine(listed in section6).
Warnings andprecautions
Consult your doctor or pharmacist before starting to take paliperidone..
If you have any of these conditions, please consult your doctor as you may need to adjust your dose or be closely monitored for a period of time.
Because, in very rare cases, a dangerously low number of a type of white blood cells necessary to fight infections in the blood has been observed in patients treated with paliperidone, your doctor may check the number of white blood cells in your blood.
Paliperidone may cause you to gain weight. Significant weight gain can negatively affect your health. Your doctor will regularly monitor your weight.
In patients treated with paliperidone, diabetes mellitus or worsening of existing diabetes mellitus has been observed. Your doctor should check for signs of increased blood sugar.In patients with pre-existing diabetes mellitus, blood sugar should be regularly monitored.
During cataract surgery in the eye, the pupil (the black circle in the middle of the eye) may not dilate as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery and this may cause eye damage.If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are taking thismedicine.
Children andadolescents
Paliperidone should not be administered to children and adolescents under 15 years of age for the treatment ofschizophrenia.
Paliperidone should not be administered to children and adolescents under 18 years of age for the treatment ofschizoaffectivedisorderon.
This is because it is unknown whether paliperidone is safe or effective in this age group.
Othermedications and paliperidone
Inform your doctor or pharmacist if you are using, have used recently, or may take othermedicaments.
Abnormalities in heart function may occur when this medication is taken with other medications for heart rhythm control or other medications such as antihistamines, antimalarials, orantipsicótics.
Since this medication primarily acts on the brain, this medication may interfere with other medications (or alcohol) that also act on it, due to the sum of effects onbrainfunction.
This medication may lower blood pressure, so you should be careful if you take this medication with other medications that also lowerbloodpressure.
This medication may reduce the effect of medications for Parkinson's disease and restless legs syndrome (e.g.,levodopa).
The effects of this medication may be affected if you take medications that influence the speed of intestinal movement (e.g.,metoclopramida).
Reduction of this medication dose should be considered when administered withvalproato.
The use of oral risperidone with this medication is not recommended as this combination may cause an increase in adverse effects.
Paliperidone should be used with caution with medications that increase the activity of the central nervous system (psycho-stimulants such as metilphenidato).
Paliperidone and alcohol
You should avoid consuming alcohol during treatment with thismedicine.
Pregnancy andlactation
If you are pregnant or breastfeeding, or if you think you may be pregnant or plan to become pregnant, consult your doctor or pharmacist before taking thismedicine.
You should not take this medication during pregnancy unless you have discussed it with your doctor.
The following symptoms may occur in newborn babies of mothers who have been treated with paliperidone in the last trimester of pregnancy (last three months of your pregnancy): tremor, rigidity, and/or muscle weakness, drowsiness, agitation, breathing problems, and difficulty feeding. If your baby develops any of these symptoms, you should contact your doctor.
You should not breastfeed your baby while taking this medication.
Driving andoperatingmachinery
During treatment with this medication, dizziness and vision problems may occur (see section 4, Possible side effects). This should be taken into account when requiring maximum attention, for example, when driving or operatingmachinery.
Paliperidone Teva contains sodium
This medication contains less than 1 mmol of sodium (23 mg) per tablet, which may be considered as “sodium-free”.
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist.médico or pharmacist..In case of doubt, consult your doctor or pharmacist again.
Use in adultsadultos
The recommended dose in adults is 6 mg once a day in the morning. Your doctor may increase or decrease it within the dosing interval of 3 mg to 12 mg once a day in case of schizophrenia or 6 mg to 12 mg once a day in case of schizoaffective disorder. This depends on how well the medication works for you.
Use in adolescents and childrenadolescentes
The recommended starting dose for the treatment of schizophrenia in adolescents aged 15 years or older is 3 mg once a day taken in the morning.
For adolescents weighing 51 kg or more, the dose can be increased within the interval of 6 mg to 12 mg once a day.
For adolescents weighing less than 51 kg, the dose can be increased to 6 mg once a day.
Your doctor will decide how much to administer to you. The amount you take depends on how well the medication works for you.
How and when to take paliperidone
This medication should be taken orally, swallowed whole with water or other liquids. Do not chew, divide, or crush it.
This medication should be taken in the mornings with breakfast or on an empty stomach, but in the same way every day. Do not alternate between taking the medication with breakfast and on an empty stomach the next day.
The active ingredient, paliperidone, dissolves once swallowed, and the coating of the tablet is eliminated from the body by the intestines.
Patients with kidney problemsriñón
Your doctor may adjust the dose of this medication according to your renal function.
Patients of advanced age
Your doctor may reduce your medication dose if your renal function is reduced.
If you take more paliperidone than you shoulddebe
In case of overdose or accidental ingestion, consult your doctor, pharmacist, or go to the nearest hospital immediately, or call the Toxicological Information Service. Telephone: 91 562 04 20 indicating the medication and the amount ingested. You may experience drowsiness, dizziness, abnormal body movements, difficulty staying upright and walking, dizziness due to reduced blood pressure, and cardiac rhythm alterations.
If you forgot to take paliperidone
Do not take a double dose to compensate for the missed doses. If you forget a dose, take the next dose the next day. If you forget two or more doses, contact your doctor.
If you interrupt the treatment with paliperidone
Do not stop taking this medication as you will lose the effects of the medication. Do not stop taking this medication unless your doctor tells you to, as the symptoms may reappear.
If you have any other doubts about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone gets them.
Inform your doctor immediately if you experience any of the following:
• Blood clots in the veins, especially in the legs (symptoms include swelling, pain, and redness of the leg), which can travel through the blood vessels to the lungs causing chest pain and difficulty breathing. If you notice any of these symptoms, seek medical advice immediately.
• You have dementia and experience a sudden change in your mental state or sudden weakness or numbness in the face, arms, or legs, especially on one side, or you have trouble speaking even for a short period of time. These may be signs of a stroke.
• You experience fever, muscle stiffness, sweating, or a decrease in consciousness (a condition known as "Neuroleptic Malignant Syndrome"). You may need medical treatment.
• You are a man and experience a prolonged or painful erection. This is known as priapism. You may need medical treatment.
• You experience involuntary rhythmic movements of the tongue, mouth, or face. You may need to stop taking this medicine.
• You experience a severe allergic reaction characterized by fever, swelling of the mouth, face, lips, or tongue, difficulty breathing, hives, and sometimes a decrease in blood pressure (anaphylactic reaction).
Very common (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Unknown (frequency cannot be estimated from available data):
The following side effects have appeared with the use of another medication called risperidone, which is very similar to paliperidone, so it is also expected to appear with paliperidone:
Other types of blood vessel problems in the brain, crepitant sounds from the lungs, severe or potentially fatal skin rash with blisters and peeling of the skin that may start in the mouth, nose, eyes, and genitals and spread to other areas of the body (Stevens-Johnson syndrome/toxic epidermal necrolysis). Problems with the eyes may also occur during cataract surgery. During cataract surgery, a condition called intraoperative floppy iris syndrome (IFIS) may occur if you are taking or have taken paliperidone. If you need to undergo cataract surgery, make sure to inform your ophthalmologist if you are taking or have taken this medication.
Additional side effects in adolescents:
Adolescents generally experienced side effects similar to those found in adults, except for the following side effects that were detected more frequently:
Reporting of side effects:
If you experience side effects, consult your doctor, pharmacist, or nurse, even if the side effects do not appear in this leaflet. You can also report them directly to the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and blister after CAD or EXP. The expiration date is the last day of the month that is indicated.
Store in the original packaging to protect it from moisture.
This medication does not require special temperature conditions for its conservation.
Medicines should not be thrown down the drains or in the trash. Dispose of the containers and medicines that you no longer need at the SIGRE point of the pharmacy. In case of doubt, ask your pharmacist how to dispose of the containers and medicines that you no longer need. By doing so, you will help protect the environment.
Composition of Paliperidone Teva
The active ingredient is paliperidone. Each prolonged-release tablet contains 3 mg, 6 mg or 9 mg of paliperidone.
The other components are macrogol, butylhydroxytoluene, povidone, sodium chloride, microcrystalline cellulose, magnesium stearate, iron oxide red (E172), hydroxypropylcellulose, and cellulose acetate in the tablet core, and hypromellose, titanium dioxide (E171), talc, and propylene glycol in the coating and lacquer, iron oxide black (E172), and propylene glycol in the printing ink. See section 2. “Paliperidone Teva contains sodium”.
Appearance of the product and contents of the package
3 mg: Film-coated, round, biconvex, white to off-white tablets with possible uneven surface and printed with the mark P3 on one side of the tablet. Diameter: approximately 9 mm.
6 mg: Film-coated, round, biconvex, yellowish-brown tablets with possible uneven surface and printed with the mark P6 on one side of the tablet. Diameter: approximately 9 mm.
9 mg: Film-coated, round, biconvex, pale pink tablets with possible uneven surface and printed with the mark P9 on one side of the tablet. Diameter: approximately 9 mm.
Paliperidone Teva is available in packs containing:
10x1, 14x1, 28x1, 30x1, 56x1, 98x1, 112x1 or 196x1 prolonged-release tablets in perforated unit-dose blisters.
Not all package sizes may be marketed.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization:
Teva B.V.
Swensweg 5
Haarlem 2031 GA
Netherlands
Responsible manufacturer:
KRKA, d.d., Novo mesto
Šmarješka cesta 6
8501
Slovenia
Or
Teva Pharma, S.L.U.
C/ C, nº 4. Polígono Industrial Malpica
50016 Zaragoza
Spain
Or
Laboratoria Qualiphar NV (Qualiphar NV)
Rijksweg 9
2880 Bornem
Belgium
For further information about this medicinal product, please contact the local representative of the holder of the marketing authorization:
Teva Pharma, S.L.U.
c/ Anabel Segura 11, Edificio Albatros B, 1st floor, Alcobendas,
28108 Madrid (Spain)
Last review date of this leaflet: November 2024
For detailed information about this medicinal product, please visit the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.